153 related articles for article (PubMed ID: 37100233)
21. Insulinoma-associated protein 1 is a sensitive and specific marker for lung neuroendocrine tumors in cytologic and surgical specimens.
Viswanathan K; Siddiqui MT; Borczuk AC
J Am Soc Cytopathol; 2019; 8(6):299-308. PubMed ID: 31345782
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of immunohistochemical expression of novel neuroendocrine marker INSM1 and histological tumor growth pattern in well-differentiated neuroendocrine tumors of the appendix: 15-year single tertiary center experience.
Koyuncuer A; Canbak T; Acar A; Şahin O
Indian J Pathol Microbiol; 2024 Apr; 67(2):282-288. PubMed ID: 38427752
[TBL] [Abstract][Full Text] [Related]
23. Paraganglioma of the cauda equina: a report of two cases with unusual histopathological features.
Matsumoto M; Abe K; Baba H; Kinoshita N; Yamauchi T; Shiraishi M; Osaki M; Hayashi T
Clin Neuropathol; 2012; 31(1):39-43. PubMed ID: 22192703
[TBL] [Abstract][Full Text] [Related]
24. Paraganglioma of the cauda equina. A case report and review of the literature.
Bak J; Olsson Y; Grimelius L; Spännare B
APMIS; 1996 Mar; 104(3):234-40. PubMed ID: 8611199
[TBL] [Abstract][Full Text] [Related]
25. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms.
Rindi G; Mete O; Uccella S; Basturk O; La Rosa S; Brosens LAA; Ezzat S; de Herder WW; Klimstra DS; Papotti M; Asa SL
Endocr Pathol; 2022 Mar; 33(1):115-154. PubMed ID: 35294740
[TBL] [Abstract][Full Text] [Related]
26. [Paraganglioma of the cauda equina with papillary pattern and cytokeratin expression: 2 potential sources of diagnostic error. Report of a case and review of the literature].
Cuesta-Mejías T; Revilla-Pacheco F; del Bosque-Patoni C; Ortiz-Hidalgo C
Gac Med Mex; 2001; 137(5):465-9. PubMed ID: 11692814
[TBL] [Abstract][Full Text] [Related]
27. Cytokeratins expression in paragangliomas of the cauda equina.
Labrousse F; Leboutet MJ; Petit B; Paraf F; Boncoeur-Martel MP; Moreau JJ; Catanzano G
Clin Neuropathol; 1999; 18(4):208-13. PubMed ID: 10442464
[TBL] [Abstract][Full Text] [Related]
28. INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.
Razvi H; Tsang JY; Poon IK; Chan SK; Cheung SY; Shea KH; Tse GM
Pathology; 2021 Feb; 53(2):170-178. PubMed ID: 32951906
[TBL] [Abstract][Full Text] [Related]
29. Paraganglioma of cauda equina: report of seven cases.
Singh NG; Sarkar C; Sharma MC; Garg A; Gaikwad SB; Kale SS; Mehta VS
Brain Tumor Pathol; 2005; 22(1):15-20. PubMed ID: 18095099
[TBL] [Abstract][Full Text] [Related]
30. Insulinoma-associated Protein 1 (INSM1) in Thoracic Tumors is Less Sensitive but More Specific Compared With Synaptophysin, Chromogranin A, and CD56.
Kriegsmann K; Zgorzelski C; Kazdal D; Cremer M; Muley T; Winter H; Longuespée R; Kriegsmann J; Warth A; Kriegsmann M
Appl Immunohistochem Mol Morphol; 2020 Mar; 28(3):237-242. PubMed ID: 30358615
[TBL] [Abstract][Full Text] [Related]
31. Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections.
Mukhopadhyay S; Dermawan JK; Lanigan CP; Farver CF
Mod Pathol; 2019 Jan; 32(1):100-109. PubMed ID: 30154579
[TBL] [Abstract][Full Text] [Related]
32. Syntaxin-1 and Insulinoma-Associated Protein 1 Expression in Breast Neoplasms with Neuroendocrine Features.
Turkevi-Nagy S; Báthori Á; Böcz J; Krenács L; Cserni G; Kővári B
Pathol Oncol Res; 2021; 27():1610039. PubMed ID: 34764822
[No Abstract] [Full Text] [Related]
33. INSM1 is a useful neuroendocrine marker to differentiate pancreatic serous cystadenoma from pancreatic well-differentiated neuroendocrine tumors in cytology and surgical specimens.
Chi Z; Xu J; Karamchandani DM; Peng L
Ann Diagn Pathol; 2024 Aug; 71():152304. PubMed ID: 38614035
[TBL] [Abstract][Full Text] [Related]
34. Paraganglioma of the cauda equina region.
Corinaldesi R; Novegno F; Giovenali P; Lunardi T; Floris R; Lunardi P
Spine J; 2015 Mar; 15(3):e1-8. PubMed ID: 25452014
[TBL] [Abstract][Full Text] [Related]
35. Insulinoma-associated Protein 1 (INSM1) Expression in Small Cell Neuroendocrine Carcinoma of the Urinary Tract.
Kim IE; Amin A; Wang LJ; Cheng L; Perrino CM
Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):687-693. PubMed ID: 31876605
[TBL] [Abstract][Full Text] [Related]
36. Expression of Insulinoma-Associated Protein 1 (INSM1) and Orthopedia Homeobox (OTP) in Tumors with Neuroendocrine Differentiation at Rare Sites.
Roy M; Buehler DG; Zhang R; Schwalbe ML; Baus RM; Salamat MS; Lloyd RV; Rosenbaum JN
Endocr Pathol; 2019 Mar; 30(1):35-42. PubMed ID: 30523500
[TBL] [Abstract][Full Text] [Related]
37. INSM1 Is Less Sensitive But More Specific Than Synaptophysin in Gynecologic High-grade Neuroendocrine Carcinomas: An Immunohistochemical Study of 75 Cases With Specificity Test and Literature Review.
Zou Q; Zhang L; Cheng Z; Guo X; Cao D
Am J Surg Pathol; 2021 Feb; 45(2):147-159. PubMed ID: 33264139
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic utility of INSM1 and GATA3 in discriminating problematic medullary thyroid carcinoma, thyroid and parathyroid lesions.
Adel Hakim S; Mohamed Abd Raboh N
Pol J Pathol; 2021; 72(1):11-22. PubMed ID: 34060284
[TBL] [Abstract][Full Text] [Related]
39. [Paraganglioma of the cauda equina].
Ugarte Elola AC; Hernández i Vidal A; Viladot i Pericé R; Royo i Salvador M; Pou i Serradell A
Neurologia; 1993 Feb; 8(2):73-7. PubMed ID: 8383986
[TBL] [Abstract][Full Text] [Related]
40. Paraganglioma of the cauda equina. Report of three cases.
Pigott TJ; Lowe JS; Morrell K; Kerslake RW
J Neurosurg; 1990 Sep; 73(3):455-8. PubMed ID: 2384784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
